In Trading, Results Matter.
Our Top 10 exits in last 5 trading days.

Vericel Corporation. Trade Record

NASDAQ:VCEL Vericel Corporation stock gains 43.64% Exit Oct 5, 2017 a Trade Record by priceseries

Trade Chart
Trade Chart VCEL Aug 28, 2017, priceSeries
About Vericel Corporation

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Trade Information
Trade Type
LONG
ReliabilityScore™
89.47
Entry Date
Aug 28, 2017
Entry Price
3.65
Sell Date
Oct 5, 2017
Sell Price
5.24
Net Gain
43.64%
Hold Time
27 Trading Days